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Abstract
Objective: The recruitment of leukocytes from circulation to sites of inflammation requires several families of
adhesion molecules among which are selectins expressed on a variety of cells. In addition, they have also been
shown to play key roles in the activation of cells in inflammation.
Methods: To explore the collective role of E-, L-, and P- selectins in OVA-induced Th2 mediated response in acute
asthma pathophysiology, ELP-/- mice were used and compared with age-matched wildtype (WT).
Results: Asthma phenotype was assessed by measuring pulmonary function, inflammation and OVA-specific serum
IgE, which were completely abrogated in ELP-/- mice. Adoptive transfer of sensitized L selectin+CD4+ T cells into
naïve ELP-/- mice which post-OVA challenge, developed asthma, suggesting that L-selectin may be critically
involved in the onset of Th2 response in asthma. Tissue resident ELP-deficient cells were otherwise functionally
competent as proved by normal proliferative response. Conclusions: Comparative studies between ELP-/- and WT
mice uncovered functional roles of these three integrins in inflammatory response in allergic asthma. All three
selectins seem to impede inflammatory migration while only L-selectin also possibly regulates activation of specific
T cell subsets in lung and airways.
Keywords: Selectin, asthma, inflammation
Introduction
The respiratory drug market is dominated by asthma and
its exacerbations (worsening symptoms, rescue medication
use, and emergency department visits or hospitalizations).
Asthma is the third leading cause of death in both devel-
oped and developing countries and annual direct and
indirect cost of healthcare is more than $50 billion in the
US alone.. mortality A small percent of non-responders
(10%) account for greater than 50% of health care costs
and it is for these and other patients with exacerbations
that alternative target redressal is not just necessary but
indispensible given the health care costs [1].
In particular, there is a need to develop drugs that con-
trol the underlying inflammatory and destructive pro-
cesses. Rational treatment depends on understanding the
underlying disease process and there have been recent
advances in understanding the cellular and molecular
mechanisms that may be involved to look for better drug
targets [2]. Inflammation is key to etiology of most
respiratory disorders and there is a fine balance between
the beneficial effects of inflammation cascades and
inflammation cascades lead to development of diseases
such as chronic asthma, rheumatoid arthritis, psoriasis,
multiple sclerosis and inflammatory bowel disease. The
specific characteristics of inflammatory response in each
disease and site of inflammation may differ but recruit-
ment and activation of inflammatory cells and changes in
structural cells remain a universal feature along with a
concomitant increase in the expression of components of
inflammatory cascade including cytokines, chemokines,
growth factors, enzymes, receptors, adhesion molecules
and other biochemical mediators [3].
The chronic airway inflammation of asthma is unique
in that the airway wall is infiltrated by T lymphocytes of
the T-helper (Th) type 2 phenotype, eosinophils, macro-
phages/monocytes and mast cells. Accumulation of
inflammatory cells in the lung and airways, epithelial des-
quamation, goblet cell hyperplasia, mucus hypersecretion
and thickening of submucosa resulting in bronchocon-
striction and airway hyperresponsiveness are important
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lating leukocytes such as Th2 lymphocytes, mature
plasma cells expressing IgE, eosinophils [5]and neutro-
phils as well as local resident and structural cells consti-
tuting the ‘respiratory membrane’ (airway epithelial cells,
fibroblasts, resident macrophages, bronchial smooth
muscle cells, mast cells etc.) contribute to the pathogen-
esis of asthma [6]. Cross-linking of IgE receptors on mast
cells releases histamines, prostaglandins, thromboxane
and leukotrienes leading to bronchoconstriction, vasodi-
lation and mucus secretion. A cascade of interactions
between cells and soluble molecules result in bronchial
mucosal inflammation and lead to airway hyperrespon-
siveness [7].
Leukocyte emigration into lung is an important event in
the pathogenesis of asthma, likely mediated by a series of
leukocyte adhesion molecule interactions with endothe-
lium of which the various ICAMs, adhesion molecules [8]
and selectins [9,10] have been found to be critically impor-
tant. Among the integrins, a4 is key in initial signaling for
sensitization as well as migration for the onset and devel-
opment of a full blown acute asthma phenotype as well as
airway remodeling in chronic asthma while b2 integrins
are solely required for mechanical migration of leukocytes
[11,12].
During inflammatory recruitment in lung and airways,
the initial contact of leukocytes with the endothelium is
mediated by selectins and their ligands inducing the roll-
ing of leukocytes along the vessel wall [13-17]. This rolling
phenomenon is a pre-requisite for the subsequent firm
adhesion and transmigration, which is mediated by mem-
bers of the integrin family, e.g. b2 integrins, and immuno-
globulin gene superfamily, e.g. intercellular adhesion
molecule-1 (ICAM-1) [18-20].Peribronchial inflammation
contributes to the pathophysiology of allergic asthma. In
many vascular beds, adhesive interactions between leuko-
cytes and the endothelial surface initiate the recruitment
of circulating cells. Such movement is believed to follow a
coordinated and sequential molecular cascade initiated, in
part, by the three members of the selectin family of carbo-
hydrate-binding proteins: E-selectin (CD62E), L-selectin
(CD62L) and P-selectin (CD62P).
The role of selectins in neutrophil trafficking in the
lungs was frequently considered negligible since the nar-
row pulmonary capillaries cannot accommodate the typi-
cal selectin-mediated rolling phenomenon. Selectins
especially did not seem necessary in lung neutrophil
sequestration since the deceleration of circulating neutro-
phils prior to their firm adherence was effectively achieved
by their mechanical retention [10]. Yet a large body of
experimental data demonstrating that selectin inhibition
(via the use of blocking antibodies or selectin antagonists
or transgenic knockout of 1 or more selectins) frequently
protected animals from Acute lung injury. [Subset-Specific
Reductions in Lung Lymphocyte Accumulation Following
intratracheal antigen Challenge in Endothelial Selectin-
Deficient Mice [21-23]. P-selectin mediated platelet-neu-
trophil interactions are critical to the development of ALI,
to which they contribute by enhancing their respective
activations, which trigger the production of TXA2 and
other inflammatory mediators [24].
In addition to being responsible for the rolling phenom-
enon, selectins have been implicated as important signaling
molecules involved in leukocyte activation as well. The
selectin gene family closely linked on mouse chr1, encodes
3 structurally related proteins that display differential
spatial and temporal expression within the vascular system.
Endotherlial cells express E-selectin, platlets express
P-selectins and leukocytes express L-selectin. Whereas
P-selectin (CD62P) is rapidly mobilized to the surface of
activated endothelium or platlets, E-selectin (CD62E)
expression is induced by inflammatory cytokines. L-selectin
(CD62L) is constitutively expressed on most leukocytes.
Selectin expression can be up-regulated under inflam-
matory conditions in experimental animals [25-28] and
humans [29]. Although there appear to be some variations
in E-selectin expression depending on the disease state,
the general consensus from these studies is that E-selectin
is most strongly expressed on endothelial cells of portal
tract vessels and hepatic venules and to a lesser degree on
sinusoidal lining cells [25]. In contrast, L-selectin is consti-
tutively present on most types of leukocytes [30]. In vitro
studies showed that E-selectin on endothelial cells can
induce up-regulation of Mac-1 (CD11b/CD18) on neutro-
phils [31]. In addition, L-selectin ligation or crosslinking
induced up-regulation of Mac-1 and priming for superox-
ide formation [19]. Thus, E-, P-, and L-selectin may have
an important function in Th2 response in OVA-induced
asthma.
The objective of this study was to investigate the func-
tional significance of E-, P- and L-selectin in an experi-
mental model of OVA-induced lung injury. OVA induce
a Th2-mediated inflammatory response characterized by
inflammatory recruitment in lungs and airways, mucus
over-secretion and airways hyperresponsiveness. Our
previous studies [11,12] have shown the involvement of
various families of adhesion molecules viz. a4b1, b2a n d
VCAM-1 facilitate leukocyte transmigration, adherence
to parenchymal cells, and Th2 response, in the pathophy-
siology of various inflammatory disease models such as
allergic asthma and aseptic peritonitis. This study eluci-
dates the effect of deletion of all three selectins in the
development of allergic asthma phenotype in mice.
Materials and methods
Animals
C57BL6 mice were used as described previously [11,12].
Wildtype (WT) and ELP-/- (was kindly donated by
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tute and Center for Cancer research, MIT, Cambridge,
MA) both on a C57BL6 background were used. All ani-
mals were maintained under SPF conditions in the ani-
mal facility of the University of Washington following
strict guidelines laid down by IACUC. (n = 5 mice per
experimental group).
Allergen sensitization and challenge
Mice were sensitized and later challenged with OVA
(Pierce, Rockford, IL) as described previously [11,12].
Mice were immunized with OVA (100 mg) complexed
with aluminium sulfate in a 0.2-ml volume, administered
by i.p. injection on day 0. On days 8 (250 mg of OVA)
and on days 15, 18, and 21 (125 mg of OVA), mice were
anesthetized briefly with inhalation of isoflurane in a
standard anesthesia chamber and given OVA by intratra-
cheal (i.t.) administration. Intratracheal challenges were
done as described previously (Iwata A, J Immunol.
2003;170:3386). Mice were anesthetised and placed in a
supine position on the board. The animal’st o n g u ew a s
extended with lined forceps and 50 ml of OVA(in the
required concentration) was placed at the back of its ton-
gue. The control goup received normal saline with alumi-
n i u ms u l f a t eb yi . p .r o u t eo nd a y0a n d0 . 0 5m lo f0 . 9 %
saline by i.t. route on days 8, 15, 18, and 21 (Figure 1).
Pulmonary function test
In vivo airway hyperresponsiveness to methacholine was
measured 24 hours after the last OVA challenge by both
invasive and non-invasive plethysmography.
Invasive plethysmography
On d 22, 24 h after the last intra-tracheal allergen
(OVA) challenge invasive pulmonary mechanics were
measured in mice in response to methacholine in the
same manner as previously described [11] with the
following modifications: a) the thorax was not opened,
b) mice were ventilated with a tidal volume of 200 μl
and respiratory rate of 120 breaths/min using a Mini-
Vent Ventilator for Mice (Harvard Apparatus, Holliston,
MA), c) mice received aerosolized solutions of metha-
choline (0, 3.125, 6.25, 12.5, 25, 50, and 100 mg/ml in
normal saline) via an AER 1021 nebulizer aerosol system
(Buxco Electronics, Inc., Wilmington, NC) with 2.5-4
micron aerosol particle size generated by NEB0126
nebulizer head (Nektar Therapeutics, San Carlos, CA),
and d) a commercial plethysmography system (Model
PLY4111 plethysmograph, MAX II amplifier and pres-
sure transducer system, and Biosystem XA software,
B u x c oE l e c t r o n i c s ,I n c . )w a su s e dt od e t e r m i n eR L as
calculated from measures of pressure and flow and
expressed as cmH2O/ml/s). Non-invasive plethysmogra-
phy (expressed as Penh) was also assessed on d 22 in
independent experiments.
Non-invasive whole body plethysmography in con-
scious, free moving, spontaneously breathing mice using
whole-body plethysmography (model PLY 3211; Buxco
Electronics, Sharon, CT) as previously described [41].
Mice were challenged with aerosolized saline or increas-
ing doses of methacholine (5, 20, and 40 mg/ml) gener-
ated by an ultrasonic nebulizer (DeVilbiss Health Care,
Somerset, PA) for 2 min. The degree of bronchoconstric-
tion was expressed as enhanced pause(Penh), a calculated
dimensionless value, which correlates with the measure-
ment of airway resistance, impedence, and intrapleural
pressure in the same mouse. Penh readings were taken
and avergared for 4 min after each nebulization chal-
lenge. Penh was calculated as follows: Penh=[(Te/Tr-1)X
(PEF/PIF), where Te is expiration time, Tr is relaxation
time, PEF is peak expiratory flow, and PIF is peak inspira-
toy flow × 0.67 co-efficient. The time for the box pres-
sure to change from a maximum to a user-defined
percentage of the maximum represents the relaxation
OVA
i.p.
Plethysmography/B
ALf/PB/BM/Lung 
tissue
OVA
i.t.
0 8 15 18 21 22
Days of treatment
Figure 1 Study protocol for development of acute allergic asthma disease model in mice.
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pressure and ends at 40%.
Cell suspensions prepared from tissues
After pulmonary function testing, the mouse underwent
exsanguination by intra-orbital arterial bleeding and
then BALF (0.4 ml three times) of both lungs. Total
BALF fluid cells were counted from a 50 ml aliquot and
the remaining fluid was centifuged at 200 g for 10 min
at 4°C and the supernatants stored at -70°C for assay of
BALF cytokines later. The cell pellets were resuspended
in FCS and smears were made on glass slides. The cells,
after air drying, were stained with Wright-Giemsa (Bio-
chemical Sciences Inc, Swedesboro, NJ) and their differ-
ential count was taken under a light microscope at 40X
magnification. Cell number refers to that obtained from
lavage of both lungs/mouse. Lung parenchyma was pre-
pared in the following way: lung mincing and digestion
was performed after lavage as described previously [13]
with 100 u/ml collagenase for 1 hr at 37°C, and filtered
through a 60# sieve (Sigma). All numbers mentioned in
this paper refer to cell sobtained from one lung/mouse.
Lung histology
Lungs of other animals of same group were were fixed
in 4% paraformaldehyde overnight at 4°C. The tissues
were embedded in paraffin and cut into 5 mm sections.
A minimum of 15 fields were examined by light micro-
scopy. The intensity of cellular infiltration around pul-
monary blood vessels was assessed by Hematoxylin and
Eosin staining. Airway mucus was identified by staining
with Alcian blue and Periodic Acid Schiff staining as
described previously [11,12]
Smear evaluation
Proportions of eosinophils and mast cells were assessed
in cytospin smears stained with Hematoxylin and Eosin
by Diff Quik stain from Fisher.
Fluorescin-activated cell sorter (FACS) analysis
Cells from hemolysed peripheral blood (PB), bone marrow
(BM), bronchoalveolar lavage (BALF), lung parenchyma
(LP), and spleen were analyzed on a FACSCalibur (BD
Immunocytometry Systems, San Jose, CA) by using the
CELLQuest program. Staining was performed by using
antibodies conjugated to fluorescin isothiocyanate (FITC),
phycoerythrin (PE), allophucocyanin (APC), Peridinin
Chlorophyll Protein (Per CP-Cy5.5) and Cy-chrome (PE-
Cy5 and PE-Cy7). The following BD pharmingen (San
Diego, CA) antibodies were used for cell surface staining:
APC-conjugated CD45 (30F-11), FITC-conjugated CD3
(145-2C11), PE-Cy5 conjugated CD4 (RM4-5), PE-conju-
gated CD45RC (DNL-1.9), APC-conjugated CD8(53-6.7),
PE-Cy5 conjugated B220 (RA3-6B2), FITC-conjugated
IgM, PE-conjugated CD19 (ID3), PE-conjugated CD21
(7G6), FITC-conjugated CD23 (B3B4), APC-conjugated
GR-1(RB6-8C5), and PE-conjugated Mac1(M1/70).
PE-Cy5 conjugated F4/80 (Cl:A3-1(F4/80)) was obtained
from Serotec Ltd., Oxford, UK.
CFU-c assay
To quantitate committed progenitors of all lineages, CFU-
C assays were performed using methylcellulose semisolid
media (Stemgenix, Amherst, N.Y.) supplemented with an
additional 50 ng of stem cell factor (Peprotech, Rocky Hill,
N.J.) per ml. Next, 50,000 cells from bone marrow,
500,000 cells from spleen, 0.01 million cells from lung and
BALF, and 10 ml peripheral blood were plated on dupli-
cate 35-mm culture dishes and then incubated at 37°C in
a5 %C O 2-95% air mixture in a humidified chamber for
7 days. Colonies generated by that time were counted by
using a dissecting microscope, and all colony types (i.e.,
burst forming units-erythroid [BFU-e], CFU-granulocyte-
macrophage [CFU-GM], and CFU-mixed [CFU-GEMM])
were pooled and reported as total CFU-C. Total CFU-c
per organ was calculated by extrapolating CFU-c against
number of plated cells to the total number of cells in the
organ.
ELISA for cytokines
Th2 cytokines (IL-4 and 5) and TNFa and IFNg in
BALF and serum (previously frozen at -70°C) were
assayed with mouse Th1/Th2 cytokine CBA (BD Bios-
ciences, San Diego, CA) following the manufacturer’s
protocol. According to the manufacturer’sp r o t o c o l .
IL-13 and Eotaxin were measured by Quantikine M kits
from R&D Systems, Minneapolis, MN.
ELISPOT
IL-4+ and IFN-g+ cells in single cell suspensions from
lung parenchyma and BALf were detected employing
standard ELIspot assays (Lee S-H, Nat Med. 2003;9:1281)
using detection and capture monoclonal antibodies and
AEC substrate reagent from BD Biosciences. Dots were
counted manually using 40X magnification.
OVA specific IgE, and IgG1 in serum
Anti-mouse IgE (R35-72) and IgG1(A85-1) from BD
Biosciences, San Diego, CA were used for measuring
OVA specific IgE and IgG1 (in serum previously frozen
at -70°C) respectively by standard ELISA procedures as
previously described [15].
T cell proliferation assay
MACS-separated CD4þ and CD8þ T cells from spleens
were stimulated in vitro with various concentrations of
stimuli (CD3/CD28, phorbol myristic acetate (PMA)/
ionomycin, irradiated antigen-presenting cells (APCs),
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responses. After 72 hours, proliferation was measured
by CellTiter96 assay from Promega (Madison, WI, USA)
measuring OD at 570 nm.
Adoptive transfer
At day 8 after i.p. sensitization, 5 × 10
6 CD4+ spleno-
cytes from both WT controls or ELP-/- mice were
purified by magnetic-activated cell sorting (MACS,
Miltenyi Biotec, Auburn, CA, USA), then injected into
the tail veins of na""ve controls or ELP-/- recipients.
T h em i c ew e r es u b s e q u e n t l yc h a l l e n g e dw i t h3i . t .
instillations of OVA over the next 72 hours, and sacri-
ficed 24 hours after the last instillation [14]. For nega-
tive control (Gr#4), CD62L-CD4+ T cells were
separated by MACS from ELP-/- donors. Gr#1 is the
positive control here.
Statistical analysis
Statistical differences among samples were tested by
Student t test. P value less than 0.05 was considered
statistically significant.
Results
Complete abrogation of composite asthma phenotype in
KO mice
Our first aim was to find out whether composite asthma
phenotype developed (Figure 1) in the absence of the
triple selctins in a knockout mouse which should indi-
c a t ew h a tr o l et h e yh a v ei nt h eo n s e to ft h ed i s e a s e
pathophysiology. We found that following allergen chal-
lenge, compared to the WT mice which develop all the
hallmarks of the composite asthma phenotype, the yard-
sticks quantified in the ELP-/- mice were all similar to
the saline treated baseline controls (Figure 2A-C) viz.
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Figure 2 Non-development of composite asthma phenotype in ELP-/- mice. Figure 2A. Pulmonary function test by non-invasive whole
body plethysmography. Functional response to increasing doses of methacholine show no increase in response from baseline in ELP-/- mice
in comparison with WT post-OVA. WT+alum (white square), WT+OVA (black square), ELP-/-+alum (white square) and ELP-/-+OVA (black square).
Figure 2B. Pulmonary function test by invasive plethysmography. Functional response to increasing doses of methacholine show no
increase in response from baseline in ELP-/- mice in comparison with WT post-OVA. [WA = WT with alum and saline treatment, EA = ELP-/- mice
same placebo treatment, WO = WT sensitized and challenged with OVA, EO = OVA treatment with ELP-/- mice.] WA (white square), WO (black
square), EA (white triangle), EO (black triangle). Figure 2C. Lung histology. Panel a, b. H&E staining of paraffin lung sections. a. WT+OVA, b.
ELP-/-+OVA; Panel c, d. Alcian blue staining of paraffin lung sections. C. WT+OVA, d. ELP-/-+OVA.
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response to increasing doses of aerosolized methacho-
line as measured by a plethysmometer nor inflammation
in the airways or lung parenchyma as detected H&E
staining of histological sections of the lung post-OVA in
the ELP-/- mice vs. WT.
Inhibition of inflammatory recruitment in airways despite
peripheral leukocytosis
Once it was clear that the preclinical parameters for
acute allergic asthma failed to develop in the knockout
mosue, we embarked on dissecting the patterns of
inflammatory recruitment from bone marrow to periph-
eral blood to lung parenchyma to the lung interstitium
which is the stage for the drama of the disease pathol-
ogy to manifest itself. Table 1A-C show that despite
increased number of mature leukocytes and progenitors
in BM and circulation of post-OVA ELP-/- mice, their
number was insignificant especially in the airways. Lung
of post-OVA ELP-/- mice show elevated number of
monocytes, macrophages and neutrophils (myeloid
population) but no eosinophils and mast cells as
opposed to the higher number of these cells in OVA-
treated WT. (Table 1, 2 and 3).
ELP-/- B cells are incapable of sequestering either total or
OVA-specific Igs
Since overall allergy depends on cross talk between the
T and B cells and a concerted and sequential interplay
between the two cell populations, our next question was
whether the knockout B cells themselves were otherwise
functionally competent? B cell function was tested by
assaying total as well as OVA-specific Igs post OVA.
Figure 3 shows that other than total IgG3, all other Igs,
notably IgE and IgG1 were significantly inhibited and
even IgG3 was decreased compared to WT+OVA
values.
Lack of inflammatory and Th2 response in KO mice
Following the analyses of the cells taking part in the
development of the allergic inflammation itself, both
locally and systemically, the next question to be
addressed was the actual amount of the cytokine media-
tors that were being synthesized and released by the
inflammatory cells both for propelling their recruitment
in the relevant sites as well as their specific functional
manifestation therein. Release of Th2 specific cytokines
was significantly downregulated in KO BALf and plasma
(Table 3) compared to OVA-treated control. Detection
of virtually no IL-4-secreting cells in all except LNX
(BALf, LP, spleen, BM, MLN, CLN, LNI) and very low
number of IFN-g-secreting cells in all but the peripheral
lymph nodes (CLN, LNX, and LNI) was found (Table 4
Figure 4, 5).
ELP-/- T cells retain normal proliferative response to
mitogenic stimuli
If the cytokine release by the knockout Th2 cells were
unsatisfactory as we found, the next querry to be
addressed was, were they functionally competent other-
wise? To assess the functional status of KO T cells, CD4+
T cells were isolated from spleen and peripheral lymph
nodes and subjected to proliferation assays to various sti-
muli (PMA, ionomycin and anti CD3/CD28) which
showed efficient proliferative response similar to WT
(Figure 6A-C). In addition, CD3 level on the T cells in
WT and ELP-/- cells before and after OVA are similar
(Table 4) and no difference in T cytokine production by
ELISPOT was observed (data not presented).
Adoptive transfer of CD62L+CD4+ splenocytes from
sensitized WT to naïve ELP-/- recipients could reverse
inhibition of asthma development
Our next question was if as we found in all the previous
quantifications, in the deleted scenario allergic asthma
failed to develop, to reverse the effects of deletion, which
cells will be most effective so that we may clearly deline-
ate the role playing of that particular cell subset that is
responsible for the pathology by virtue of their expression
of the triple selctins, we did the following elimination
experiment by various permutations and combinations.
Our most obvious candidate was the CD4+ T cells. To
assess whether adoptively transferred CD4+ T cells from
sensitized wildtype mice, where all three selectins are in
place, could reverse the non-development of asthma phe-
notype in ELP-/- mice, adoptive transfer of the aforemen-
tioned cells from spleen of senstitized WT mice were
transferred by tail vein injection to naïve ELP-/- mice fol-
lowed by OVA challenge as described in Materials and
Methods. Surprisingly, we found that these ELP-/- did
Table 1 Total number of cells (×10
6) in various tissues
BM/femur PB/ml Spleen BALf/2lungs LP/2lungs
WT+alum 14.28 ± 2.38 4.17 ± 1.01 103.14 ± 31.95 0.68 ± 0.03 1.8 ± 0.63
WT+OVA 31.35 ± 11.95 7.36 ± 2.01 167.45 ± 45.97 8.4 ± 2.22 3.14 ± 0.95
ELP-/-+alum 29.54 ± 2.08* 15.31 ± 0.41* 280.43 ± 38.57* 0.78 ± 0.005 3.79 ± 0.07*
ELP-/-+OVA 33.18 ± 1.06* 15.5 ± 0.77* 247.63 ± 10.36* 0.81 ± 0.013* 5.6 ± 0.17*
Total number of cells (x10
6) in different tissues.
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cant asthma phenotype (Gr#2) compared to either the
Grs# 3 or 4 where CD4+ T cells from spleen of sensitized
ELP-/- mice were used. The experiment was validated by
Gr#1 (positive control). (Table 5 and Figure 7)
Functionally incompetent dendritic cells in knockout mice
ruled out
We also wanted to check whether the regulatory T cells
and dendritic cells were similar in the knockout mice.
Table 6 shows that both WT and KO tissues showed
similar expression of Treg and dendritic cells.
Discussion
A similar protective effect as was observed in a4-/- and
b2-/- mice in our earlier studies in the acute allergic
asthma model, was also observed here with the ELP-/-
mice [32]. This raises the question of redundancy of the
roles of all these cell adhesion molecules, each cardinal
in their individual capacities in cellular migration in
inflammation and each affecting specific cellular compo-
nents in the inflammatory cascade. So the fulcrum of
the following discussion in an effort to interpret the
observations described in this paper shall revolve around
(a) the role played by all three selectins in context with
the cells involved in the onset, development and mainte-
nance of allergy and associated inflammation in acute
Table 2 Total number of different types of leukocytes (x10
6)in various tissues
BM/femur Mononuclear PMN Eos
WT+alum 8.61 ± 1.92 5.13 ± 1.56 0.53 ± 0.02
WT+OVA 14.68 ± 3.79 11.48 ± 3.3 5.17 ± 1.22
ELP-/-+alum 19.27 ± 2.48* 9.53 ± 1.02* 0.73 ± 0.06
ELP-/-+OVA 19.56 ± 5.59¶ 13.3 ± 4.11¶ 0.31 ± 0.04¶
PB/ml Lymphocyte Monocyte Basophil PMN Eosinophil
WT+alum 2.68 ± 0.16 0.14 ± 0.06 0.03 ± 0.009 1.17 ± 0.28 0.12 ± 0.01
WT+OVA 2.39 ± 0.43 1.6 ± 0.13 0.11 ± 0.003 1.34 ± 0.36 1.9 ± 0.25
ELP-/-+alum 9.67 ± 2.01* 0.57 ± 0.03* 0.07 ± 0.004 2.41 ± 0.56* 0.17 ± 1.01
ELP-/-+OVA 9.21 ± 1.09¶ 0.49 ± 0.12¶ 0.08 ± 0.002¶ 5.45 ± 0.38¶ 0.25 ± 0.07¶
BALf/2lungs Lymphocyte Monocyte Macrophage PMN Eosinophil Mast cell
WT+alum Entirely epithelial cells and monocytes/macrophages
WT+OVA 1.93 ± 0.38 1.17 ± 0.19 2.11 ± 0.12 1.61 ± 0.33 0.03 ± 0.003 0.033 ± 0.001
ELP-/-+alum Only epithelial cells and monocytes/macrophages
ELP-/-+OVA Only epithelial cells and monocytes/macrophages
LP/2lungs Lymphocyte Monocyte Macrophage PMN Eosinophil Mast cell
WT+alum 0.2 ± 0.09 0.8 ± 0.02 0.48 ± 0.32 0.3 ± 0.09 0 0
WT+OVA 0.72 ± 0.04 0.44 ± 0.11 0.79 ± 0.11 0.6 ± 0.03 0.57 ± 0.13 0.012 ± 0.001
ELP-/-+alum 0.41 ± 0.02* 1.65 ± 0.35* 1.07 ± 0.04* 0.65 ± 0.02 0 0
ELP-/-+OVA 0.51 ± 0.03 2.01 ± 0.41¶ 1.22 ± 0.37¶ 1.35 ± 0.03¶ 0 0
Number of cells (× 10
6) in various cell subsets in different tissues.
Table 3 Total number of CFU-c in various tissues
BM/femur PB/ml BALf/2 lungs LP/2 lungs
WT+alum 45892 ± 1541 160 ± 34 3 ± 0.2 59 ± 12
WT+OVA 76894 ± 1376 1020 ± 69 872 ± 37 850 ± 14
ELP-/-+alum 61268 ± 3497* 740 ± 45* 11 ± 5* 121 ± 47*
ELP-/-+OVA 63550 ± 3492 845 ± 117¶ 14 ± 6.3¶ 269 ± 68¶
Number of progenitor cells in various tissues evaluated by CFU-c. The
numbers denoting progenitors have been rounded to the nearest whole
number. n = 5/group. * denotes p value < 0.05 compared to WT+alum and ¶
denotes p value < 0.05 compared to WT+OVA.
Serum concentration of Ig WT vs. ELP-/- OVA asthma
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Figure 3 Serum concentration of immunoglobulins in ELP-/- vs.
WT post-OVA. Serum from infra-orbital bleeding of the experimental
mice, collected in heparinized tubes, were frozen at -70°C and later
methods described in [41] were used to detect total and OVA-
specific immunoglobulin concentration. Presented values are data
pooled from 2 independent experiments with 5 mice per
experimental group measured in dulicate in 96-well format. *
denotes p value < 0.05 compared to WT+OVA values.
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Page 7 of 14asthma, (b) their role in the etiology of the disease or
co-operative functions at later stages of the disease man-
ifestation, and (c) whether pathways traversed by these
adhesion molecules intersect, overlap at certain points
or are indeed redundant. We shall try and address each
point in our discussion of the data in the following
paragraphs.
F i r s to fa l l ,a st h ed a t ai no u rs t u d ys h o w s ,d e s p i t e
increased and extensive peripheral leucocytosis, espe-
cially in eosinophils, deletion of all three selectins leads
to a complete inhibition of the development of the
asthma phenotype in the OVA-treated ELP-/- mouse.
The failure of the eosinophils to travel firstly to the lung
and thence to the airways to elicit the downstream
effects of composite asthma phenotype may have been
abrogated due to the absence of either E- or L- selectin
or all three. Let us try and eliminate the possible
candidates.
Previous studies [33] have shown a key role for
P-selectin in modulating leukocyte behavior, e.g. rag-
weed induced recruitment of eosinophils to the perito-
neum suggests a crucial role for P-selectin in Eos
recruitment. Neither E- nor L-selectin appear to mediate
leukocyte recruitment in TNF-a induced inflammation
or thioglychollate induced peritonitis. We should keep
in mind, however, that all three selectins co-operate at
some level to influence eosinophil homeostasis, whereas
P selectin is the only selectin whose absence impairs the
recruitment of these cells to the inflamed peritoneum,
the combined absence of P- and E-selectins seems to
lead to the complete abrogation of the allergic response
into the development of an asthma phenotype [34].
However, the conclusive role of L selectin vs. all three is
somewhat controversial. Previous works by different
groups have presented somewhat disparate results.
A study with an anti-L-selectin antibody or L-selectin
gene knock out mice could not prevent development of
asthma [35]. Other groups have shown that neither L- nor
E-selectin contributed to sinusoidal neutrophil sequestra-
tion or transmigration. Yet other groups have shown that
adoptive transfer of splenic lymphocytes from Cockroach
antigen- (CRA) primed E- and P- selectin deficient cells
into naive wild-type (WT) mice produced the same level
of airway hyperreactivity as transfers from CRA-primed
WT into naive WT hosts, indicating similar peripheral
immunization and [36] similar serum IgE production the
selectin-deficient and WT animals, indicating that the
Th2-driven isotype switch was unaffected by the genetic
alterations. Thus both P- and E-selectin contribute to
CRA-induced peribronchial inflammation and airway
hyperreactivity [37].
Exclusive role of L selectin in OVA asthma was shown
by the following studies: While OVA sensitized/chal-
lenged ICAM-1-deficient mice showed decreased levels
of B220+ lymphocytes in the BALf, OVA-sensitized/
challenged L-selectin deficient mice demonstrated signif-
icantly reduced numbers of CD3+ lymphocytes and
increased B220+ lymphocytes in BALf suggesting a cru-
cial role for ICAM-1 in airway inflammation and AHR
in asthma (as corroborated by our earlier studies [11,12]
but L-selectin plays a more selective role in the develop-
ment of AHR but independent of airway inflammation
in this animal model of asthma [38].
Thus earlier studies have shown that both cell adhe-
sion molecules (i.e. selectins and integrins) play key
roles in cell trafficking and in the lung they regulate
Table 4 Cytokine concentration (pg/ml) in plasma and
BALf post-OVA in WT vs
Plasma Mean
WT ELP-/-
IL-2 41.6 ± 7 4.95 ± 1.75*
IFN-g 40.89 ± 1.19 2.86 ± 0.88*
TNF-a 9.1 ± 0.4 nd
IL-10 78.05 ± 22.65 6.55 ± 3.05*
IL-4 81.95 ± 0.85 nd
IL-5 244.8 ± 22.8 87.7 ± 6.6*
IL-13 136.1 ± 0.8 nd
Eotaxin 337.33 ± 40.32 nd
MMP-9 96696.45 ± 158.11 70603 ± 40399.7*
SDF-1a 665.6 ± 73.7 48.65 ± 7.55*
KC 23.8 ± 2 nd
TGF-b 19063.55 ± 4377.45 nd
BALf Mean
WT ELP-/-
IL-2 36.6 ± 0.7 38.4 ± 0.2
IFN-g 144 ± 27.5 nd
TNF-a 20.4 ± 0.8 5.2 ± 0.6*
IL-10 8.7 ± 0.6 2.15 ± 0.15*
IL-4 94.75 ± 9.35 nd
IL-5 94.85 ± 13.35 10.1 ± 0.8*
IL-13 131.8 ± 3.9 9.1 ± 8.3*
Eotaxin 431 ± 84.7 12 ± 0.2*
MMP-9 945.3 ± 23.9 371.05 ± 67.25*
SDF-1a 260.8 ± 17.5 35.75 ± 2.95*
KC 17.9 ± 0.6 6.95 ± 0.45*
TGF-b 467 ± 15.7 nd
ELP-/-.
nd = not detected
The concentration of cytokines was measured by outsourcing to Pierce,
Endogen by multiplexing with their patented technology. Presented data
evaluation was outsourced to Pierce Endogen. Searchlight™ technology was
used to assay the following cytokines in triplicate and data presented is mean
of samples from 5 mice per group and pooled from 2 independent
experiments ± SEM. Other than IL-2 all Th1 and Th2 as well as other
associated cytokines levels were decreased in KO BALf while a universal
downregulation was found in all cytokines in plasma. Presented data is
average of triplicate of samples (n = 5/group) ± SEM of 2 independent
experiments. *p value < 0.01 compared to WT+alum (baseline) values.
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Page 8 of 14leukocyte extravasation, migration within the intersti-
tium, cellular activation, and tissue retention. However,
adoptive transfer experiments show very clearly that
sensitized CD4+ T cells from WT spleens were able to
reverse the effect of ELP deletion in developing an
asthma phenotype although of a smaller magnitude than
sensitized and challenged WT. It follows that CD4+ T
cells from WT will express only L-selectin of all the
three selectins and therefore L-selectin alone was suffi-
cient to reverse the effects of E-, L- and P- selectin dele-
tion [39].
The significant reduction in levels of all immunoglo-
bulins (Figure 3) indicate a serious problem with Ig
sequestering by ELP-/- B cells. If CD62L+CD4+ T cells
from sensitized WT spleen could develop asthma in
naïve ELP-/-, it also indicates that development of
asthma may not be entirely dependent on ELP-/- B cells
in the spleens of these ELP-/- recipients or that the 5
million CD62L+ sensitized CD4+T cells are sufficiently
potent to go into circulation and generate at least
t h r e s h o l da m o u n to fI g Ef o rr e q u i r e da i r w a yi n f l a m m a -
tory response. As seen from ELISPOT assays (Figure 4)
only the axillary lymph nodes showed increase in IL-4+
expressing cells which may have provided the required
mobilizing force for the nearby airway inflammation in
the adoptively transferred recipients.
The role of selectins in neutrophil trafficking in the
lungs was frequently considered negligible since the nar-
row pulmonary capillaries cannot accommodate the typi-
cal selectin-mediated rolling phenomenon. Furthermore,
selectins did not seem necessary in lung neutrophil
sequestration since the deceleration of circulating neutro-
phils prior to their firm adherence was effectively achieved
by their mechanical retention [40]. Yet a large body of
experimental data demonstrating that selectin inhibition
(via the use of blocking antibodies or selectin antagonists
or transgenic knockout of one or more selectins) fre-
quently protected animals from Acute Lung Injury [17].
In the light of the above data let us try and explain
what the status of the various cells playing key role in
ELISPOT IL-4+
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Figure 4 ELISPOT of Th2 cells in lymphoid tissues. cells.. Number of IL-4+ cells averaged from triplicate wells of a 96-well ELISPOT plate ±
SEM of 2 independent experiments. * denotes p value < 0.01 compared to WT+OVA.
Banerjee Journal of Inflammation 2011, 8:19
http://www.journal-inflammation.com/content/8/1/19
Page 9 of 14the onset and establishment of the TH2 inflammatory
response to the allergen OVA are likely to be. First, the
dendritic cells [41] and alveolar macrophages [42]
whose responses are critical for antigen presentation to
the naïve T cells, need P- and L-selectin and the b2
integrins and L selctins respectively may be considered.
These cells therefore are practically dysfunctional when
L-selectins are absent on the KO mice. They are neither
capable of processing the signal nor coupling with their
other accessories that mediate adhesion in the inflam-
matory cascade.
If we assume that in the ELP-/- mice, there was no
response to the allergen in the first place because the
cells themselves were incapable of sequestering the
allergen for presentation, the absence of any TH2
response and therefore inflammatory recruitment
downstream and the consequent non-manifestation of
the composite asthma phenotype may be explained.
However, (Table 3) increased number of mature leuko-
cytes and progenitors in BM and circulation of post-
OVA ELP-/- mice butinsignificantly so in the airways
But elevated in the lung parenchyma particularly of
monocytes, macrophages and neutrophils (myeloid
population) but no eosinophils and mast cells is some-
what confusing because it seems that the systemic
response did happen to the OVA challenge but migra-
tion to the tissues was arrested.
The adoptive transfer of only ELP+ CD4+ T lympho-
cytes reinstating the asthma phenotype indicates con-
clusively that it was the afferent arm of the Th2
immune response that was affected. However, since
human asthma involves a complex interplay of cells,
early and late asthma responses sometimes intermingle
especially during exacerbations in the chronic phase of
allergic asthma hence the assumption that the afferent
limb of the immune response was likely affected. Also,
since the role of CD4+ T cells in eosinophil recruit-
ment is firmly established [43-45] triple selectin dele-
tion may be held responsible for preferably affecting
the afferent arm of the response by giving the OVA-
treated mouse such a clean respiratory tree and no
hyperreactivity to methacholine.
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MLN- acute asthma in WT vs. ELP KO
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Figure 5 ELISPOT of Th1 cells in lymphoid tissues. cells.. Number of IFN-g+ cells averaged from triplicate wells of a 96-well ELISPOT plate ±
SEM of 2 independent experiments. * denotes p value < 0.01 compared to WT+OVA.
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Page 10 of 14As for attenuation of both Th1 and Th2 cytokines in
the ELP-/- OVA-treated mice, the non-occurrence of
the first lap of the journey (the afferent limb of the
immune response) probably prevents activation and
recruitement of the cytokine secreting cells [46]. The
elegant study by David A. Randolph et al [47] show that
while both Th1 and Th2 cells are recruited to the
airways, Th1 cells predominate early and Th2 cells pre-
dominate late. On this assumption we conclude that it
is not exclusively the Th2 cells that are recruited and
further reduction in Th1 and Th2 cytokine secretion
correlates with the complete non-occurrence of the first
line response in the development of the composite
asthma phenotype in the knockout animals.
In the light of our findings [11,12] with the acute and
chronic OVA models, the b2 integrins, which, compared
to a4 integrins preferably co-localize with the P- and L-
selectins in these cells, there seems to be a disruption of
a similar pathway that also prevents development of
asthma in the CD18 knockout mice. However, release of
Th2 specific cytokines being significantly downregulated
in KO BALf and plasma (Table 4) and virtually no IL-4-
secreting cells being detected in all tissues systemic as
well as local, (Table 4, 5) a universal lack of response in
processing the stimulus viz. OVA, is indicated. The cells
that were hyperproliferated in bone marrow and blood,
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Figure 6 Functional tests for T cells. Unseparated T cells from spleen and peripheral lymph nodes (pooled cervical and axillary lymph nodes)
were evaluated for proliferative responses to various stimuli and readout taken at 570 nm following MTT assay (Promega) A. Proliferation assay
with PMA+ionomycin; B. Proliefration to anti CD3/CD28 with cells from spleen, and C. with cells from the same lymph nodes as above.
Table 5 Adoptive transfer groups
Donors Recipients Asthma phenotype
Gr#1 CD4+ from Sensitized WT Naïve WT +
Gr#2 CD4+ from Sensitized WT Naïve ELP-/- +
Gr#3 CD4+ from Sensitized ELP-/- Naïve WT -
Gr#4 CD4+ from Sensitized ELP-/- Naïve ELP-/- -
Donors were always sensitized mice and CD4+ T splenocytes were isolated by
MACS and adoptively transferred into naïve recipients (5 × 10
6) by tail vein
injection. Splenocytes were collected a week after sensitization of donor by i.
p. injection of OVA-alum. The recipients were then challenged by intra-
tracheal OVA instillation over the next 72 h and sacrificed and evaluated 24 h
after the last challenge.
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Page 11 of 14were also incapable of sequestering the requisite cyto-
kines to mount a response. Interestingly peripheral
lymph nodesrelease higher levels of TH1 cytokines indi-
cating that deletion of all three selectins may be critical
for skewing the inflammatory responses towards a TH2
phenotype at least in an acute allergic set up. Whether
the situation will reverse in the chronic phase as in our
work with the b2 integrin knockout mice [12] is yet to
be studied.
This is the first report that clearly delineates the role of
L-selectin from the other selectins and show that: (a)
ELP-/- mice are incapable of mounting a full fledged
asthma response despite impressive peripheral leukocyto-
sis possibly due to a failure to sequester initial response
to allergen exposure; (b) inflammatory response in air-
ways is almost non-existent despite some myeloid migra-
tion into their lungs; (c) ELP-/- T cells are functionally
active and responsive whereas ELP-/- B cells are incap-
able of sequestering total as well as allergen specific
WT-WT= Sens CD62L+CD4+ into naïve WT(Gr#1) 
WT-KO=Sens CD62L+CD4+ into naïve ELP-/- (Gr#2)
KO-WT=Sens CD62L-CD4+ into naïve WT (Gr#3) 
KO-KO=Sens CD62L-CD4+ into naïve ELP-/-T(Gr#4)
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Figure 7 Non-invasive whole body plethysmography to assess
pulmonary function in adoptively transferred recipients. (n=4
per group). [Refer Table 2 for adoptive transfer groups.] Gr#1 (white
square), Gr#2 (Black square), Gr#3 (white circle), Gr#4 (black circle).
Table 6 Number of total and LECAM+ regulatory T cells and dendritic cells in various hematopoietic and non-
hematopoietic tissues in WT vs.
Total
CD45+ CD3+ CD4+ CD8+ CD4+ CD11c+
CD25+
BM
WO 9.67 ± 2.31 0.15 ± 0.06 0.02 ± 0.001 0.12 ± 0.09 0.19 ± 0.06 0.020 ± 0.004
EO 10.16 ± 3.34 0.18 ± 0.07 0.03 ± 0.015 0.14 ± 0.03 0.18 ± 0.07 0.018 ± 0.006
PB
WO 26.90 ± 4.41 9.49 ± 4.76 3.59 ± 1.05 5.90 ± 0.87 1.38 ± 0.56 1.18 ± 0.76
EO 29.99 ± 5.67 6.49 ± 2.13 2.22 ± 1.02 4.27 ± 0.56 1.05 ± 0.74 1.61 ± 0.13
Spleen
WO 234.89 ± 54.87 118.69 ± 32.87 48.79 ± 11.09 69.90 ± 11.21 27.01 ± 53.91 ± 4.98
EO 212.73 ± 43.98 109.09 ± 18.24 44.76 ± 4.97 63.33 ± 14.32 30.73 ± 41.61 ± 9,61
MLN
WO 38.74 ± 4.73 15.22 ± 5.52 4.85 ± 1.09 10.37 ± 2.21 4.95 ± 0.54 7.00 ± 0.43
EO 36.10 ± 9/65 17.48 ± 5.98 4.95 ± 0.67 12.53 ± 3.86 5.30 ± 0.04 7.42 ± 1.09
CLN
WO 16.35 ± 3.65 4.41 ± 1.06 1.452 ± 0.04 2.89 ± 0.03 12.91 ± 0.54 2.78 ± 0.54
EO 14.00 ± 4.45 6.36 ± 0.64 5.05 ± 0.43 1.31 ± 0.54 3.51 ± 1.85 2.68 ± 0.31
LNI
WO 168.37 ± 7.54 8.67 ± 2.32 2.76 ± 0.54 5.91 ± 1.09 2.82 ± 0.06 3.98 ± 0.43
EO 21.75 ± 3.85 10.53 ± 0.65 2.980.54 ± 7.55 ± 2.03 3.19 ± 1.07 4.47 ± 1.14
LNX
WO 11.90 ± 3.28 5.61 ± 0.43 3.93 ± 0.54 3.68 ± 0.54 2.43 ± 0.87 2.26 ± 1.09
EO 13.06 ± 6.90 5.94 ± 1.33 4.71 ± 2.44 2.82 ± 0.98 3.28 ± 0.54 2.50 ± 0.23
LP
WO 0.70069 ± 0.01 0.01962 ± 0.0030.004 0.00294 ± 0.003 0.01668 ± 0.003 0.09459 ± 0.003 0.00090 ± 0.00001
EO 0.71086 ± 0.04 0.01987 ± 0.00327 ± 0.001 0.01660 ± 0.004 0.09761 ± 0.004 0.00092 ± 0.00004
KO mice.
Cell suspension was prepared either by flushing or homogenizing tissues such as bone marrow (BM) cells were prepared by flusing femurs, PB (peripheral blood
cells were prepared by hemolyzing whole blood to remove RBCs, LP (lung parenchyma) cells were prepared by homogenizing exsanguinated lung tissue and
BALf (bronchoalveolar lavage fluid) cells were prepared by flushing airways in the exsangunated lung, spleen cell suspension was prepared by flushing the
spleen and MLN (mesenteric lymph node), LNI (Inguinal lymph node), CLN (cervical lymph node) and LNX (axillary lymph node) cells were prepared by similar
method. The cells were resuspended in 1X PBS with 5% BSA and stained with fluorochrome conjugated antibodies and quantified by flow cytometry. WO
denotes Wild type mice challenged with OVA and EO denotes ELP-/- challenged with OVA. Presented data is average of triplicate of samples (n = 5/group) ±
SEM of 2 independent experiments. *p value < 0.01 compared to WT+alum (baseline) values.
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“primed” during initial sensitization by OVA-alum com-
plex may have been ineffective (which is more likely) or
(2) the primed B cells when matured into plasma cells
fail to properly sequester OVA-specific IgE (which
although an attractive explanation, cannot explain how in
the adoptive transfer experiments (Figure 7 and Table 5),
naïve ELP-/- recipients could successfully mount an
asthma response when transplanted with CD4+ WT
T cells which could happen only if the sensitization
phase occurred successfully. Nevertheless the fact that
they were able to manifest “functional asthma” (as shown
by lung function test) despite unprimed B cells may indi-
cate that the robust response was due mainly to the
CD4+ T cell response that were equipped with the L-
selectin and the endothelium of the challenged mouse
having their E-selectins intact and lastly, P-selectins on
the recipient platlets which may have played a key role in
neutrophil sequestration (Table 1, 2 and 3); (d) sensitized
CD62L+ CD4+ T cells adoptively transferred into naïve
ELP-/- recipients could reverse the effects of ELP dele-
tion and non-development of asthma; and lastly (e) the
axillary lymph nodes may be key to mobilize IL-4+ cells/
IL-4 for Th2 response and inflammatory recruitment in
the airways the significance of which at this point is
unclear.
Due to the essential role played by these cell adhesion
molecules in lung inflammation, all selectin family mem-
bers (including L-selectin, P-selectin, and E-selectin)
appear to be important therapeutic targets [48]. Indeed,
Revotar Biopharmaceuticals AG is developing the drug
under license from Encysive, which is a CD62L antagonist
(TBC-1269) for the potential treatment of asthma, COPD,
VILI, ALI and ARDS.
Conclusion
E-, L-, and P- selectins are important drug targets for
asthma. Locally applicable combination therapies with
small molecular antagonists or antibodies may be useful
in acute allergic asthma treatment regimens to supple-
ment other conventional therapies.
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